FDA Approves Keytruda Combination Therapy for Invasive Bladder Cancer

The U.S. FDA has approved Merck's MRK Keytruda (pembrolizumab), and its longer-acting Keytruda Qlex formulation, each in combination with Padcev (enfortumab vedotin) from PFE and partner Astellas, as neoadjuvant treatment before surgery followed by adjuvant treatment after bladder-removal surgery for adults with muscle-invasive bladder cancer (MIBC). The decision expands the regimen's reach from cisplatin-ineligible patients to all MIBC patients who are candidates for cystectomy, regardless of cisplatin eligibility.

The approval rests on strong late-stage data: the combination cut the risk of tumor recurrence, progression, or death by roughly 50%, and the risk of death by about 35%, versus standard of care in cisplatin-eligible patients. Regulators framed it as the first and only regimen for MIBC regardless of cisplatin eligibility, positioning the Keytruda-Padcev pairing as a potential platinum-free standard of care.

For the companies, the label expansion enlarges the addressable patient pool for two of oncology's highest-profile franchises. Keytruda remains Merck's flagship revenue driver, while Padcev is a cornerstone of Pfizer's oncology portfolio acquired through Seagen. The read-through is incremental rather than transformational, but it reinforces both franchises ahead of looming patent and competitive pressures. What to watch is uptake in the earlier-stage neoadjuvant setting and payer coverage for the higher-cost combination.

Related Stocks

• PFE